Free tool
Drug Trial Radar
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
64
Recruiting, any sponsor type, condition "hyperlipidemia"
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed982
64 trials
Showing 1 to 25, recently updated first.
- Study of MAR001 in Adults With Elevated Triglycerides and Remnant CholesterolPivotal-lookingRecruiting
Marea TherapeuticsIndustry
NCT07028749 · 316 participants (planned) · Start Jun 30, 2025 · Primary completion Nov 2027
Drug: MAR001; Placebo · For: Hypertriglyceridemia
Sites: Anniston, Alabama; Mobile, Alabama; Little Rock, Arkansas · 62 sites in all
Beijing Jiake Ruikang Pharmaceutical Technology Co., Ltd.Industry
NCT07937254 · 44 participants (planned) · Start Oct 19, 2026 · Primary completion Jul 30, 2027
Drug: JAR-2203; Placebo · For: Lipid Metabolism Disorders; Healthy Volunteers - Male and Female; Hyperlipoproteinemia(a)
Sites: Beijing, China
- A Study of Bempedoic Acid/Ezetimibe/High-intensity Statin in Patients Without Cardiovascular EventsPivotal-lookingRecruiting
Daiichi SankyoDaiichi Sankyo (DSNKY)
NCT07474649 · 103 participants (planned) · Start Sep 14, 2026 · Primary completion Jun 1, 2028
Drug: Bempedoic acid; Ezetimibe and 2 more · For: Coronary Atherosclerosis; Mixed Dyslipidemia; Hypercholesterolemia
Sites: Berlin, Germany; Hamburg, Germany; Mainz, Germany · 12 sites in all
- Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular InterventionPivotal-lookingRecruiting
Duke UniversityAcademic, hospital or other
NCT06909565 · 6,000 participants (planned) · Start Jul 23, 2025 · Primary completion Oct 2029
Drug: Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL; Normal Saline (Placebo) · For: Percutaneous Coronary Intervention; Peripheral Endovascular Intervention
Sites: Alexander City, Alabama; Birmingham, Alabama; Huntsville, Alabama · 153 sites in all
- A Study of VERVE-102 (LY4636581) in Adults With or at High Risk for Cardiovascular DiseasePivotal-lookingRecruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT07839936 · 175 participants (planned) · Start Sep 24, 2026 · Primary completion Aug 2028
Drug: VERVE-102; Placebo · For: Atherosclerosis; Cardiovascular Disease; Hypercholesterolemia
Sites: DeSoto, Texas
Fondazione SISA (Societa Italiana per lo Studio della Arteriosclerosi)Academic, hospital or other
NCT06362473 · 15,000 participants (planned) · Start Aug 4, 2015 · Primary completion Dec 31, 2036
Drug: Lipid-lowering treatments · For: Familial Hypercholesterolemia; Genetic Disorder
Sites: Sesto San Giovanni, Italy
- Pemafibrate for Symptomatic ICAS RCTPivotal-lookingRecruiting
Tokyo Women's Medical UniversityAcademic, hospital or other
NCT07562178 · 270 participants (planned) · Start May 26, 2026 · Primary completion Mar 31, 2028
Drug: Pemafibrate · For: Intracranial Atherosclerotic Disease (ICAD); Hypertriglyceridaemia; Stroke (CVA) or TIA
Sites: Toyoake, Japan; Yachiyo, Japan; Yoshida, Japan · 42 sites in all
Eli Lilly and CompanyEli Lilly (LLY)
NCT07269210 · 60 participants (planned) · Start Dec 8, 2025 · Primary completion Mar 2027
Drug: Solbinsiran; Placebo · For: Severe Hypertriglyceridemia
Sites: Phoenix, Arizona; Tucson, Arizona; Beverly Hills, California · 41 sites in all
- A Clinical Study of Enlicitide (MK-0616) in Adults With Hyperlipidemia in India (MK-0616-038)Pivotal-lookingRecruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT07821944 · 150 participants (planned) · Start Oct 15, 2026 · Primary completion Nov 26, 2027
Drug: Enlicitide Decanoate · For: Hyperlipidemia; Hypercholesterolemia
Sites: Belagavi, India; New Delhi, India
Ionis Pharmaceuticals, Inc.Ionis Pharmaceuticals (IONS)
NCT07604974 · 72 participants (planned) · Start May 12, 2026 · Primary completion Sep 2027
Drug: ION775 · For: Hypertriglyceridemia; Severe Hypertriglyceridemia
Sites: Lincoln, California; Aurora, Colorado; Boca Raton, Florida · 18 sites in all
Corsera HealthIndustry
NCT07229118 · 80 participants (planned) · Start Nov 28, 2025 · Primary completion Feb 2027
Drug: COR-1004; Placebo · For: Hyperlipidemia
Sites: Christchurch, New Zealand; Wellington, New Zealand
- Study of Zodasiran in Adolescent Participants With Homozygous Familial HypercholesterolemiaPivotal-lookingRecruiting
Arrowhead PharmaceuticalsIndustry
NCT07473843 · 10 participants (planned) · Start Oct 2026 · Primary completion Jul 2028
Drug: Zodasiran · For: Homozygous Familial Hypercholesterolemia
Sites: St Louis, Missouri; Viborg, Denmark; Warsaw, Poland
Eli Lilly and CompanyEli Lilly (LLY)
NCT06451770 · 132 participants (planned) · Start Oct 30, 2024 · Primary completion Dec 2027
Drug: VERVE-201 · For: Hypercholesterolemia; Hypertriglyceridemia; Refractory Hyperlipidemia
Sites: Garden Grove, California; Clearwater, Florida; Miami Lakes, Florida · 18 sites in all
Arrowhead PharmaceuticalsIndustry
NCT07223658 · 78 participants (planned) · Start Dec 22, 2025 · Primary completion Jul 2027
Drug: ARO-DIMERPA; Placebo · For: Hyperlipidemia; Mixed
Sites: Charlestown, Australia; Morayfield, Australia; East Melbourne, Australia · 19 sites in all
- A Extension Study to Evaluate the Safety and Efficacy of HRS-7249 in Patients With HypertriglyceridemiaPivotal-lookingRecruiting
Fujian Shengdi Pharmaceutical Co., Ltd.Industry
NCT07799688 · 400 participants (planned) · Start Sep 11, 2026 · Primary completion Oct 15, 2028
Drug: HRS-7249 Injection; HRS-7249 Injection · For: Hyperlipidemia
Sites: Jinan, China; Shanghai, China
Meir Medical CenterAcademic, hospital or other
NCT06206759 · 2,000 participants (planned) · Start May 1, 2024 · Primary completion Feb 1, 2027
Drug: administration of vitamin C · For: Hypertriglyceridemia
Sites: Kfar Saba, Israel
- A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Rosuvastatin on LDL-C in Patients With HypercholesterolaemiaPivotal-lookingRecruiting
AstraZenecaAstraZeneca (AZN)
NCT07619118 · 200 participants (planned) · Start Sep 10, 2026 · Primary completion May 28, 2027
Drug: Placebo to match laroprovstat/rosuvastatin 1,2,3; Placebo to match laroprovstat/rosuvastatin 4 and 5 more · For: Hypercholesterolaemia
Sites: Sun City West, Arizona; Gardena, California; Lomita, California · 45 sites in all
- A Study of STX-1150 in Participants With Elevated Low-Density Lipoprotein Cholesterol (LDL-C)Recruiting
Monash UniversityAcademic, hospital or other
NCT07428473 · 64 participants (planned) · Start Jun 30, 2026 · Primary completion Dec 30, 2028
Drug: STX-1150 · For: Elevated LDL-C and High Cholesterol
Sites: Clayton, Australia; Papatoetoe, New Zealand; Christchurch, New Zealand
- Study of Plozasiran in Adults With Severe Hypertriglyceridemia at Risk of Acute PancreatitisPivotal-lookingRecruiting
Arrowhead PharmaceuticalsIndustry
NCT06880770 · 288 participants (planned) · Start Apr 24, 2025 · Primary completion Mar 2029
Drug: Plozasiran; Placebo · For: Severe Hypertriglyceridemia
Sites: Los Angeles, California; Santa Clarita, California; New Haven, Connecticut · 140 sites in all
- A Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractory DyslipidemiasRecruiting
CRISPR Therapeutics AGIndustry
NCT07491172 · 90 participants (planned) · Start Jun 21, 2024 · Primary completion Jun 2027
Drug: CTX310 · For: Cardiovascular; Metabolic Disease; Dyslipidemias and 7 more
Sites: Hialeah, Florida; Jacksonville, Florida; Orlando, Florida · 17 sites in all
- Long-term Safety and Tolerability of Inclisiran in Participants With HeFH or HoFH Who Have Completed the Pediatric ORION-16, ORION-13, ORION-20, or ORION-19 StudiesPivotal-lookingRecruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT05682378 · 195 participants (planned) · Start Feb 10, 2023 · Primary completion Mar 25, 2032
Drug: Inclisiran · For: Heterozygous or Homozygous Familial Hypercholesterolemia
Sites: Boca Raton, Florida; New York, New York; Cincinnati, Ohio · 52 sites in all
- A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Laroprovstat, Rosuvastatin and Placebo on LDL-C in LLT-naïve Patients.Pivotal-lookingRecruiting
AstraZenecaAstraZeneca (AZN)
NCT07619131 · 600 participants (planned) · Start Aug 12, 2026 · Primary completion Jul 30, 2027
Drug: Laroprovstat; Rosuvastatin 1 and 6 more · For: Hypercholesterolaemia
Sites: Dothan, Alabama; Chandler, Arizona; Phoenix, Arizona · 152 sites in all
- A Trial to Evaluate the Efficacy and Safety of SHR-1918 in Patients With HyperlipidemiaPivotal-lookingRecruiting
Beijing Suncadia Pharmaceuticals Co., LtdIndustry
NCT07230730 · 900 participants (planned) · Start Jan 13, 2026 · Primary completion Oct 2027
Drug: SHR-1918; SHR-1918 placebo · For: Hyperlipidemia
Sites: Hangzhou, China
Eli Lilly and CompanyEli Lilly (LLY)
NCT06164730 · 85 participants (planned) · Start Apr 30, 2024 · Primary completion Oct 2026
Drug: VERVE-102 · For: Heterozygous Familial Hypercholesterolemia; Premature Coronary Heart Disease
Sites: Dothan, Alabama; Pomona, California; Boca Raton, Florida · 27 sites in all
Vanderbilt University Medical CenterAcademic, hospital or other
NCT04941599 · 72 participants (planned) · Start Feb 14, 2024 · Primary completion Jun 30, 2027
Drug: 2-Hydroxybenzylamine · For: Familial Hypercholesterolemia
Sites: Nashville, Tennessee
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.